Portfolio

Company: argenx b.v. - Visit website
Fund: Thuja Capital Healthcare Fund I
Year: 2008
Status: Active

argenx is monoclonal antibody company employing proprietory superior therapeutic antibody discovery platform to develop own antibody product portfolio.

Company: Avantium B.V. - Visit website
Fund: AlpInvest Life Sciences
Year: Prior to 2008
Status: Realized

Avantium is a Dutch service and R&D company. Avantium provides innovative high-throughput R&D services and technologies to the pharmaceutical, chemical and energy industries. Our position was sold in a secondary transaction.

Company: Bioceros B.V. - Visit website
Fund: Thuja Capital Healthcare Fund I
Year: 2008
Status: Realized

Bioceros is active in the field of protein therapeutics, and offers producer cell line generation services; it also aims to develop an own therapeutic monoclonal antibody pipeline. Our position was sold to a strategic investor.

Company: BioXell - Visit website
Fund: AlpInvest Life Sciences
Year: Prior to 2008
Status: Realized

BioXell was a research and development biopharmaceutical company with globally recognised leadership in Vitamin D and its in-depth understanding of the molecular basis of inflammation. The company was initially listed on the Swiss stock exchange and subsequently acquired by Cosmo Pharmaceuticals.

Company: Breonics - Visit website
Fund: AlpInvest Life Sciences
Year: Prior to 2008
Status: Realized

Breonics, Inc. is a biomedical research and development company on the cutting edge of innovative medical products for the clinical organ transplant and tissue replacement markets.

Company: Cavadis B.V. - Visit website
Fund: Thuja Capital Healthcare Seed Fund I
Year: 2009
Status: Active

Cavadis is a biomarker company aiming to develop in vitro diagnostics for cardiovascular risk assessment.

Company: Coley - Visit website
Fund: AlpInvest Life Sciences
Year: Prior to 2008
Status: Realized

Coley Pharmaceutical Group discovers, develops and commercializes a new class of drugs that stimulate the human immune system to treat and prevent cancer, asthma, allergy and infectious diseases. The company was initially listed on NASDAQ and subsequently acquired by Pfizer.

Company: Cristal Therapeutics - Visit website
Fund: Thuja Capital Healthcare Seed Fund I
Year: 2012
Status: Active

Cristal Therapeutics (formerly known as Cristal Delivery) is a pharmaceutical company developing a new class of nanomedicine based on its proprietary polymeric technologies, registered as CriPec®.  Cristal Delivery’s mission is optimise the therapeutic performance of drugs and thereby improve patient care.

Company: Curacyte - Visit website
Fund: AlpInvest Life Sciences
Year: Prior to 2008
Status: Realized

Curacyte is an advanced biopharmaceutical company dedicated to the development of new therapeutics for acute and critical care. The company was acquired by Wilex.

Company: DCPrime B.V. - Visit website
Fund: Thuja Capital Healthcare Seed Fund I
Year: 2010
Status: Active

DCPrime is a biotech company with a proprietary allogeneic dendritic cell line as a platform to derive and develop the next generation therapeutic dendritic cancer vaccines.

Company: Develogen - Visit website
Fund: AlpInvest Life Sciences
Year: Prior to 2008
Status: Realized

DeveloGen is a biology driven specialty pharmaceutical company focusing on the development of treatments for metabolic disorders, such as diabetes, obesity and metabolic syndrome. The company was acquired by Evotec.

Company: DrugAbuse Sciences - Visit website
Fund: AlpInvest Life Sciences
Year: Prior to 2008
Status: Realized

DrugAbuse Sciences was a specialty pharmaceutical company dedicated to improving the treatment of alcohol and substance abuse and dependence. The company assets have been acquired by Elbion (now part of Biotie).

Company: Enanta - Visit website
Fund: AlpInvest Life Sciences
Year: Prior to 2008
Status: Realized

Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best-in-class small molecule drugs in the anti-infectives field. The company is listed on the NASDAQ.

Company: Encare Biotech - Visit website
Fund: Thuja Capital Healthcare Seed Fund II
Year: 2014
Status: Active

Encare Biotech is a spin-off of Utrecht UMC, dedicated to develop antibody therapeutics to prevent chronic heart failure as a consequence of a myocardial infarction.

Company: Epicept - Visit website
Fund: AlpInvest Life Sciences
Year: Prior to 2008
Status: Realized

EpiCept Corporation is a specialty niche pharmaceutical company. Epicept’s objective is to address unmet medical needs in cancer and pain management. The company is listed on the OTCQX and Stockholm Stock Exchange.

Company: Fabpulous B.V. - Visit website
Fund: Thuja Capital Healthcare Seed Fund I
Year: 2009
Status: Active

Fabpulous develops a handheld disposable plasma separation device with embedded in vitro diagnostic test capability (lateral flow). The first application is a rapid h-FAPB test as an aid in the early diagnosis of a heart infarct.

Company: Galapagos - Visit website
Fund: AlpInvest Life Sciences
Year: Prior to 2008
Status: Realized

Galapagos is a biotechnology company focused on the identification of disease modifying drug targets and the subsequent development of breakthrough medicine based on these targets. The company is listed on Euronext.

Company: Hemics B.V. - Visit website
Fund: Thuja Capital Healthcare Seed Fund I
Year: 2011
Status: Active

Hemics is a medical technology company (Philips spin-out), developing an imaging apparatus to measure and monitor rheumatoid arthritis disease activity in the joints of the hands.

Company: Indigo Diabetes - Visit website
Fund: Thuja Capital Healthcare Fund II
Year: 2016
Status: Active

Indigo Diabetes is a Belgian startup developing novel glucose sensor technology based on photonics, thus avoiding the need for frequent calibration

Company: Ingenium - Visit website
Fund: AlpInvest Life Sciences
Year: Prior to 2008
Status: Realized

Ingenium Pharmaceuticals is a drug discovery and development company focused on generating the biological information critical to the development of therapeutics, specifically in the area of pain management and inflammatory disease. The company was acquired by ProBiodrug AG.

Company: Intercell - Visit website
Fund: AlpInvest Life Sciences
Year: Prior to 2008
Status: Realized

Intercell is a biotechnology company focused on the development of vaccines against infectious diseases and cancer, initially listed on the Vienna Stock Exchange, and subsequently merged into Valneva.

Company: Mellon Medical B.V. - Visit website
Fund: Thuja Capital Healthcare Seed Fund I
Year: 2013
Status: Active

Mellon Medical B.V. is a Dutch specialist medical technology company that develops and commercializes innovative surgical instruments to allow for single-handed stitching.

Company: MILabs - Visit website
Fund: Thuja Capital Healthcare Fund II
Year: 2016
Status: Active

MILabs is a company based in Utrecht, that develops and sells state of the art molecular imaging devices, for preclinical use. In addition, MILabs is developing a clinical SPECT scanner that will have unprecedented imaging capabilities, allowing doctors to well beyond what they can image today.

Company: NightBalance B.V. - Visit website
Fund: Thuja Capital Healthcare Seed Fund I
Year: 2011
Status: Active

NightBalance is a medtech company developing and commercializing a patient-friendly device to treat positional sleep apnea.

Company: NutriLeads - Visit website
Fund: Thuja Capital Healthcare Seed Fund II
Year: 2015
Status: Active

Wageningen based company active in the field of medical nutrition and functional foods. Currently develops a food ingredient with immune system enhancing properties to help combat infections.

Company: Okapi Sciences N.V. - Visit website
Fund: Thuja Capital Healthcare Fund I
Year: 2008
Status: Realized

Okapi develops antiviral drug products to treat viral diseases in pet animals and livestock. The company was acquired by Aratana Therapeutics Inc.

Company: Omrix - Visit website
Fund: AlpInvest Life Sciences
Year: Prior to 2008
Status: Realized

OMRIX biopharmaceuticals is a marketing stage biotechnology company that develops and markets a unique surgical sealant, as well as a suite of immunology and hemophilia products. The company was initially listed on NASDAQ and subsequently acquired by J&J.

Company: TheraSolve N.V. - Visit website
Fund: Thuja Capital Healthcare Fund I
Year: 2011
Status: Active

TheraSolve develops a skin patch technology (embedded electronics) to improve drug treatment compliance.

Company: Vernalis - Visit website
Fund: AlpInvest Life Sciences
Year: Prior to 2008
Status: Realized

Vernalis is a development-stage pharmaceutical company listed on the London Stock Exchange.